CPAP and BiPAP for Sleep Apnea

Positive airway pressure (PAP) therapy represents the primary non-surgical intervention for obstructive and central sleep apnea, a condition affecting an estimated 30 million adults in the United States (American Academy of Sleep Medicine). CPAP (Continuous Positive Airway Pressure) and BiPAP (Bilevel Positive Airway Pressure) are the two dominant device classes, each operating through a distinct pressure delivery mechanism suited to different clinical profiles. Understanding the structural differences between these modalities — and the regulatory and clinical boundaries that govern their use — is foundational to the broader pulmonary care landscape covered on this site.

Definition and scope

CPAP delivers a single, fixed air pressure continuously throughout the breathing cycle, preventing airway collapse during sleep. BiPAP, by contrast, delivers two distinct pressure levels: a higher inspiratory positive airway pressure (IPAP) and a lower expiratory positive airway pressure (EPAP). This bilevel structure reduces the work of exhalation against pressure, which makes BiPAP tolerable for patients who cannot adapt to the sustained pressure of CPAP.

Both device classes fall under the jurisdiction of the U.S. Food and Drug Administration (FDA) as Class II medical devices, regulated under 21 CFR Part 868 (Anesthesiology Devices), and require a physician prescription for dispensing. The regulatory context for pulmonary care, including durable medical equipment (DME) reimbursement rules, is governed separately through the Centers for Medicare & Medicaid Services (CMS), which sets compliance thresholds that patients must meet to maintain insurance coverage — typically demonstrated adherence of at least 4 hours of use per night on 70% of nights over a consecutive 30-day period (CMS Local Coverage Determination LCD L33718).

A third variant, APAP (Auto-titrating Positive Airway Pressure), adjusts pressure automatically within a set range in response to detected airflow obstruction. APAP is classified alongside CPAP devices by the FDA but operates algorithmically rather than at a fixed pressure setting.

How it works

PAP therapy functions by pneumatically splinting the upper airway open. A motorized unit draws ambient air, filters it, and pressurizes it before delivering it through a sealed mask interface — typically nasal pillows, a nasal mask, or a full-face mask — worn during sleep. The pressurized air creates a positive-pressure column in the pharynx that counteracts the collapse of soft tissue structures (soft palate, uvula, tongue base) responsible for apnea events.

The mechanism differs between CPAP and BiPAP at the pressure-delivery level:

  1. CPAP: A single fixed pressure (commonly 4–20 cm H₂O) is maintained continuously. The patient exhales against this pressure throughout the night.
  2. BiPAP: Two pressures are programmed — IPAP (commonly 8–25 cm H₂O) activates during inhalation and EPAP (commonly 4–20 cm H₂O) activates during exhalation. The pressure differential (IPAP minus EPAP) must be at least 4 cm H₂O to qualify as a bilevel device under CMS criteria.
  3. APAP: An algorithm monitors airflow, snoring vibration, and mask leak in real time, adjusting delivery pressure breath-by-breath within clinician-set minimum and maximum thresholds.

Humidification is a standard integrated feature across device classes. Heated humidifier chambers reduce mucosal dryness and improve adherence, a factor documented in adherence research published in the Journal of Clinical Sleep Medicine (JCSM).

Common scenarios

PAP therapy is indicated across a spectrum of sleep-disordered breathing severity and comorbid conditions. The apnea-hypopnea index (AHI) — the number of apnea and hypopnea events per hour of sleep measured during a sleep study — is the primary metric used to characterize disease severity and guide device selection.

CPAP is the standard first-line therapy for:
- Moderate-to-severe obstructive sleep apnea (AHI ≥ 15 events/hour)
- Mild obstructive sleep apnea (AHI 5–14 events/hour) with documented daytime hypersomnolence, hypertension, or cardiovascular comorbidity
- Patients without significant cardiopulmonary compromise who can tolerate fixed pressure

BiPAP is typically prescribed when:
- The patient has failed CPAP due to expiratory pressure intolerance despite CPAP optimization and comfort features
- The required therapeutic pressure exceeds approximately 15 cm H₂O, at which point bilevel delivery reduces the breathing effort burden
- Comorbid conditions are present, including obesity hypoventilation syndrome (OHS), COPD with nocturnal hypoventilation, or neuromuscular diseases affecting respiratory muscle function
- Central sleep apnea or complex sleep apnea syndrome is diagnosed, sometimes requiring BiPAP with a backup respiratory rate (BiPAP-ST)

Patients presenting with snoring and daytime sleepiness are typically evaluated through polysomnography or home sleep apnea testing before device selection is made.

Decision boundaries

The clinical decision between CPAP, BiPAP, and APAP is governed by a structured set of criteria drawn from the American Academy of Sleep Medicine (AASM) clinical practice guidelines, CMS coverage determinations, and individual patient factors.

Key decision boundaries include:

  1. AHI threshold: CMS requires an AHI ≥ 5 events/hour for any PAP device coverage; AASM guidelines recommend treatment at AHI ≥ 15 or AHI ≥ 5 with qualifying symptoms (AASM Clinical Practice Guidelines).
  2. Pressure ceiling: When in-lab titration establishes a therapeutic pressure at or above 15 cm H₂O on CPAP, transition to BiPAP is a standard clinical consideration to reduce effort and improve tolerance.
  3. Hypoventilation: Patients with documented nocturnal hypoventilation (PaCO₂ ≥ 45 mmHg while awake, as defined by arterial blood gas) require bilevel or volume-assured pressure support (VAPS) rather than standard CPAP.
  4. CPAP failure criteria: CMS defines CPAP failure as either intolerance due to high pressure or persistent AHI ≥ 15 on CPAP at maximum tolerated pressure, both of which support coverage transition to BiPAP.
  5. Mask interface: Independent of device class, mask fit and seal directly affect therapy efficacy. A leak rate exceeding 24 L/min (the threshold flagged in most device compliance reports) degrades pressure delivery and AHI reduction.

Device titration — the process of identifying the optimal therapeutic pressure — occurs either during an in-laboratory polysomnography titration study or through APAP auto-titration over a home trial period, with clinician review of downloaded compliance data. The selection of titration method and device class remains a physician-directed decision, informed by polysomnographic findings, comorbid diagnosis codes, and patient tolerance profiles.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)